Ignite Creation Date:
2024-05-06 @ 6:19 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05624749
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2022-11-07
Brief Title:
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus SIRIUS-SLE 2
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-21
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01-26
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-01-23
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-07
First Submit QC Date:
November 21 2022
Study First Post Date:
2022-11-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-02
Last Update Post Date:
2024-07-08
Last Update Post Date Type:
ACTUAL